Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
COVID-19: early-phase trial registry
68 of 299 indexed COVID-19 trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #30 of 28,707 conditions by registered trial count.
299 US clinical trials · 68 currently recruiting · #30 of 28,707 conditions by registered trial count
COVID-19: 299 US clinical trials tracked, 68 recruiting.
COVID-19 is the subject of 299 registered US clinical trials on ClinicalTrials.gov, 68 of them currently open to new participants. 42 are in Phase 3-4 (later-stage) and 83 in Phase 1-2 (earlier-stage). The most active sponsor is National Institute of Allergy and Infectious Diseases (NIAID), running 16 of these trials.
Enrollment posture brief
Registry condition covid-19
OPEN 68 | RECR 23% | LATE 42 | EARLY 83 | RANK #30 | SPON 16
Volume-matched condition peers
Nearest open-share peer: Hypogonadism (23% recruiting · 22 trials)
COVID-19 lists 68 open slots (23% of 299 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for COVID-19 on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
COVID-19 is recruiting below its size-band peers.
68 of 299 indexed trials (22.7%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of COVID-19 trials is spread across many organizations.
National Institute of Allergy and Infectious Diseases (NIAID) accounts for 16 of 299 trials (5.4%). 173 distinct sponsors appear on at least one study for this condition label.
-
Typical COVID-19 enrolment sits around 245 participants.
Median target enrolment is 245 among the 299 trials that report a genuine target (sentinel values excluded). 96 of those (32.1%) plan for fewer than 100 participants.
-
COVID-19 splits between interventional and observational designs.
196 interventional and 103 observational studies make up this index (65.6% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
299 total, page 1 of 6
Addressing Vaccine Acceptance in Carceral Settings Through Community Engagement
Yale University
NCT05796505
COVID-19 Risk Assessment for Hospitalization Outcomes and Epidemiology Efficacy
Aventyn
NCT04678193
A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age
BioNTech SE
NCT07300839
Preparedness Through Respiratory Virus Epidemiology and Community Engagement
University of California, San Diego
NCT07147517
Conversations You Want About Corona Virus Disease (COVID-19)
Wake Forest University Health Sciences
NCT05191420
Respiratory Virus Sampling and Repository
National Institute of Allergy and Infectious Diseases (NIAID)
NCT05266222
Influenza & COVID-19 Obstetric and Perinatal Epidemiology Study in India
Boston University
NCT06168019
COVID-19 Vaccines International Pregnancy Exposure Registry
Pregistry
NCT04705116
A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children
BioNTech SE
NCT05543616
COVID-19 International Drug Pregnancy Registry
Pregistry
NCT05013632
KIDney Injury in Times of COVID-19 (KIDCOV)
University of California, San Francisco
NCT04705766
The SINCERE Intervention to Address COVID-19 Health Disparities
Andrea Wallace
NCT05228886
COVID-19 Survivorship Registry
NYU Langone Health
NCT04527315
Dime La VerDAD: Verify, Debunk, and Disseminate
University of Chicago
NCT06417762
Vaccine Responses to SARS-CoV-2 and Other Emerging Infectious Diseases
National Institute of Allergy and Infectious Diseases (NIAID)
NCT05078905
Clinical Validation of the Aptitude Medical Systems Metrix COVID-19 Test
Aptitude Medical Systems
NCT06744660
Viral Infections in Healthy and Immunocompromised Hosts
National Institute of Allergy and Infectious Diseases (NIAID)
NCT01306084
CU-COMMITS: COVID-19 Care in Black and Latino Communities and Households. Clinical and Molecular Outcomes of SARS-CoV-2
Columbia University
NCT05467930
A Multi-Site Clinical Evaluation of the LIAISON NES FLU A/B, RSV & COVID-19 Assay in Symptomatic Patients
DiaSorin Molecular
NCT06672692
ARMOR Study: COVID-19 Seroprevalence Among Healthcare Workers
Columbia University
NCT04367857
Connecting Friends and Health Workers to Boost COVID-19 Vaccination in Latino Communities
Johns Hopkins University
NCT06128928
A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Variant-containing Formulations
ModernaTX
NCT07089706
Outpatient Treatment With Anti-Coronavirus Immunoglobulin
University of Minnesota
NCT04910269
Determinants of SARS (Severe Acute Respiratory Syndrome)-COV2 (COVID-19) Persistence After Convalescence
Columbia University
NCT04448145
COVID-19 Outcome Prediction Algorithm
University of California, Los Angeles
NCT05471011
Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID
Wes Ely
NCT06631287
Cardiac Magnetic Resonance Tissue Characterization in COVID-19 Survivors
Weill Medical College of Cornell University
NCT05164744
Methodist Health System COVID-19 Patient Registry
Methodist Health System
NCT04477889
Dysbiosis & Long COVID
University of Chicago
NCT06825819
A Multimodal Parent-focused Intervention for Vulnerable Populations in the Bronx
Albert Einstein College of Medicine
NCT04991467
NIH RECOVER Tissue Pathology: Understanding the Long-Term Impact of COVID-19
NYU Langone Health
NCT05292274
The Impact of COVID-19 on Maternal and Neonatal Outcomes
Johns Hopkins University
NCT05197621
A Pilot Clinical Evaluation of Astepro® Nasal Spray for Management of Early SARS-CoV-2 Infection
University of Chicago
NCT06008860
Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study
Ansun Biopharma
NCT03808922
A Study to Explore the Role of Gut Flora in COVID-19 Infection
ProgenaBiome
NCT04359836
Impact of Aerosol Box Use During Cardiopulmonary Arrest: A Multicenter Study
KidSIM Simulation Program
NCT05868239
Convalescent Plasma Collection and Treatment in Pediatrics and Adults
West Virginia University
NCT04376034
Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults
CastleVax
NCT07215520
COVID-19 Coagulopathy Extension Study
University of Iowa
NCT05334615
Positron Emission Tomography (PET) Imaging of Thrombosis
Massachusetts General Hospital
NCT03830320
EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe Disease
Pfizer
NCT05261139
Vale+Tú Salud: Corner-Based Trial to Test a Latino Day Laborer Program Adapted to Prevent COVID-19
The University of Texas Health Science Center, Houston
NCT06821113
Natural History of Systemic and Nasal Mucosal Immunity to Influenza and SARS-CoV-2 in Adults After Vaccination
National Institute of Allergy and Infectious Diseases (NIAID)
NCT04794829
Neural and Cognitive Consequences of COVID-19 Survival
San Francisco Veterans Affairs Medical Center
NCT06208943
A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes
National Institute of Allergy and Infectious Diseases (NIAID)
NCT07221162
Percutaneous Electrical Nerve Field Stimulation (PENFS) in Patients With Post Concussion Syndrome (PCS)
Children's Hospital of Orange County
NCT04978571
REmotely Monitored, Mobile Health Supported Multidomain Rehabilitation Program With High Intensity Interval Training for COVID-19
Duke University
NCT05218083
Mitoquinone/Mitoquinol Mesylate as Oral and Safe Postexposure Prophylaxis for Covid-19
University of Texas Southwestern Medical Center
NCT05886816
COVID-19 Health Adjustments in Nutrition, General Wellness, and Exercise
Indiana University
NCT07128095
Passive Detection- SARS-CoV-2 (COVID-19) A&M Breathalyzer (PROTECT Kiosk) for Operational Medicine
The Geneva Foundation
NCT06402318
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 28 |
| Phase 2 | 55 |
| Phase 3 | 31 |
| Phase 4 | 11 |
Top Sponsors
Named interventions
Most-linked intervention names on COVID-19 records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on COVID-19 trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this COVID-19 page
299 registered trials, 68 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 68 COVID-19 trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Institute of Allergy and Infectious Diseases (NIAID) sponsors the most COVID-19 trials on record, review their full trial history before evaluating a specific study. See National Institute of Allergy and Infectious Diseases (NIAID)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This COVID-19 condition card totals 299 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.